Transplantation & Cellular Therapy Meetings

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma.

Anakinra failed to reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

Obecabtagene autoleucel improved outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia with low-risk CAR-HEMATOTOX scores in the 1/2 FELIX trial.

Neel Bhatt, MD, discussed the importance of long-term patient monitoring following hematopoietic cell transplantation.

Valentina Ardila, MD, encouraged further research to understand the complex interplay between obesity, immune response, and transplant outcomes.

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

Rahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.

Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.

Michael Scordo, MD, discussed findings from a phase 2 study investigating new antithymocyte globulin dosing models for ex vivo CD34-selected allogeneic stem cell transplants.

Stephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Balancing cost and efficiency remains at the crux of autologous stem cell transplants for multiple myeloma treatment.

Kayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.

Alice Bertaina, MD, discussed combining T-allo10 gene therapy with stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

The latest developments across the fields of stem cell transplantation and cellular therapy were presented at the 2024 Tandem Meetings in San Antonio, Texas, from February 21-24, 2024.

Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.

Promising survival data for Orca-T was also matched in a population of patients with hematologic malignancies aged 55 years and older.

The combination of belumosudil plus ruxolitinib demonstrated response and tolerability in patients with steroid-refractory or steroid-dependent chronic graft-vs-host disease.

Lisocabtagene maraleucel given as a single administration led to rapid responses in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.

Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.

Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.